July 2025

PULMONARY

ANTIBODY REBOUND LIMITS EFFICACY OF DESENSITIZATION FOR LUNG TRANSPLANT CANDIDATES

A recent study revealed important insights into the challenges of desensitization protocols for lung transplantation candidates. High levels of human leukocyte antigen (HLA) antibodies can be a barrier for lung transplantation due to the risk of antibody-mediated rejection. Desensitization treatments aim to lower these antibody levels, but their efficacy and safety remain a concern for patients awaiting organs from deceased donors.

Digging Into Study Details
The study involved a detailed analysis of 15 highly sensitized lung transplant candidates who underwent plasmapheresis-based desensitization treatment. Among the 14 who successfully received transplants, the study authors observed a noteworthy decrease in overall antibody levels in those who underwent transplantation shortly after their treatment. Specifically, two of four patients transplanted within 15 days post-treatment benefited from sustained antibody reductions.

In contrast, those transplanted more than 15 days after their initial treatment displayed significant antibody rebound, with seven out of 10 patients returning to pre-treatment levels or exceeding them within a few weeks. Only three patients exhibited lasting reductions, and these were notably evident months after treatment.
Importantly, when compared to a control group receiving post-transplant treatment, the desensitization cohort did not show significant differences in survival or acute rejection rates.

The Takeaway
The findings emphasize that while plasmapheresis-based desensitization can effectively lower HLA antibody levels, antibody rebound significantly limits its success for many candidates. The study authors suggest that optimal strategies may involve prioritizing desensitization in patients with high lung composite allocation scores who are likely to be transplanted soon after treatment. Alternatively, implementing robust post-transplant immunosuppression could be a more effective approach for managing highly sensitized patients.
​
These insights are crucial for informing clinical practices and enhancing outcomes for lung transplantation candidates facing high antibody levels.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like